To assess the effects of interferon gamma (IFN-gamma) on very primitive hematopoietic progenitor cells, CD34(2+)CD38- human bone marrow cells were isolated and cultured in a two-stage culture system, consisting of a primary liquid culture phase followed by a secondary semisolid colony assay. CD34(2+)CD38- cells needed at least the presence of interleukin 3 (IL-3) and kit ligand (KL) together with either IL-1, IL-6, or granulocyte-colony-stimulating factor (G-CSF) in the primary liquid phase in order to proliferate and differentiate into secondary colony-forming cells (CFC). Addition of IFN-gamma to the primary liquid cultures inhibited cell proliferation and generation of secondary CFC in a dose-dependent way. This was a direct effect since it was also seen in primary single cell cultures of CD34(2+)CD38- cells. The proliferation of more mature CD34+CD38+ cells, however, was not inhibited by IFN-gamma, demonstrating for the first time that IFN-gamma is a specific and direct hematopoietic stem cell inhibitor. IFN-gamma, moreover, preserves the viability of CD34(2+)CD38- cells in the absence of other cytokines. IFN-gamma could, therefore, play a role in the protection of the stem cell compartment from exhaustion in situations of hematopoietic stress and may be useful as stem cell protecting agent against chemotherapy for cancer.
Skip Nav Destination
Article navigation
Article|
September 01 1994
Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells.
H W Snoeck,
H W Snoeck
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
D R Van Bockstaele,
D R Van Bockstaele
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
G Nys,
G Nys
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
M Lenjou,
M Lenjou
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
F Lardon,
F Lardon
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
L Haenen,
L Haenen
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
I Rodrigus,
I Rodrigus
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
M E Peetermans,
M E Peetermans
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
Z N Berneman
Z N Berneman
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
H W Snoeck
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
D R Van Bockstaele
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
G Nys
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
M Lenjou
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
F Lardon
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
L Haenen
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
I Rodrigus
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
M E Peetermans
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Z N Berneman
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1994) 180 (3): 1177–1182.
Citation
H W Snoeck, D R Van Bockstaele, G Nys, M Lenjou, F Lardon, L Haenen, I Rodrigus, M E Peetermans, Z N Berneman; Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells.. J Exp Med 1 September 1994; 180 (3): 1177–1182. doi: https://doi.org/10.1084/jem.180.3.1177
Download citation file:
Suggested Content
Email alerts
Advertisement